Abbott Laboratories stock after-hours at EUR 87.96: minus 0.85 percent versus prior close
Published on 09/30/2026 at 19:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Abbott Laboratories stock was at EUR 87.96 in after-hours trading at 7:42 p.m. CEST on September 30, 2026, down 0.85 percent versus the prior close of EUR 88.71 at Lang & Schwarz. On the same day, Abbott announced the U.S. commercial launch of SimpleScreen CRC, an FDA-approved blood-based colorectal cancer screening test for adults age 45 and older at average risk, according to Abbott.
After-hours trading
The Lang & Schwarz price was EUR 87.96 at 7:42 p.m. CEST, with a bid of EUR 87.82 and an ask of EUR 88.10. The further course of after-hours trading at Lang & Schwarz until 11:00 p.m. CEST is shown by the continuously updated real-time quote of Abbott Laboratories stock.
SimpleScreen CRC launch
Abbott said SimpleScreen CRC is developed and manufactured by Freenome and exclusively commercialized by Abbott. The test uses circulating cell-free DNA from a blood draw and joins Abbott's Cologuard Plus stool-based test in its colorectal cancer screening portfolio. Abbott said eligible patients with Medicare Part B will have no out-of-pocket costs, while Medicare Advantage patients may have out-of-pocket costs. The company also said a positive result should be followed by a timely colonoscopy, consistent with American Cancer Society recommendations, in the company's release.
Third-quarter reporting date
Abbott said it will announce third-quarter 2026 financial results on October 21 before the market opens. The announcement will be followed by a live webcast at 8:00 a.m. Central time, or 9:00 a.m. Eastern time, according to PR Newswire.
